Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
Sponsor: GlaxoSmithKline
Terminated
Slow accrual
Other terminated trials from GlaxoSmithKline
Other Estrogen Receptor-positive Breast Cancer trials with similar outcome
This PHASE2 trial investigates Estrogen Receptor-positive Breast Cancer and Human Epidermal Growth Factor 2 Negative Carcinoma of Breast and is currently terminated or withdrawn. GlaxoSmithKline leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Aug 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Terminated PHASE2
-
Apr 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Feb 2017 — Apr 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- National Cancer Institute (NCI)
- University of Arizona
For direct contact, visit the study record on ClinicalTrials.gov .